This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: November 21, 2010
Last updated: November 24, 2010
Last verified: November 2010
The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.

Condition Intervention
Osteoporosis Device: Dual energy X-ray absorptiometry

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Diagnosis of Osteoporosis [ Time Frame: 3 month ]
  • Diagnosis of Osteoporosis [ Time Frame: 3 ]

Estimated Enrollment: 20
Study Start Date: December 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Dual energy X-ray absorptiometry
    Device which measures bone density

Ages Eligible for Study:   60 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Man at the minimum age of 60 years.
  2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
  3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria:

  1. Usage of systemic steroids more than once during the 12 months prior to the study.
  2. Usage of systemic steroids during the month prior to the study.
  3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01246375

Contact: Eitan Segal, B.Sc 97236947507

Tel Aviv medical center Not yet recruiting
Tel Aviv, Israel
Contact: Eitan segal, B.Sc    97236947507   
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Yehuda Schwartz, M.D Tel Aviv Medical Center
  More Information

Responsible Party: Dr. Yehuda Schwartz, Tel Aviv medical center Identifier: NCT01246375     History of Changes
Other Study ID Numbers: TASMC-10-SY-454-CTIL
Study First Received: November 21, 2010
Last Updated: November 24, 2010

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases processed this record on July 24, 2017